XBIO: Bagan rega target Xenetic Biosciences Inc.

Xenetic Biosciences (XBIO) develops advanced oncology platforms, leveraging global biomaterial logistics to protect its R&D and profitability. Business resilience relies on therapy trial results, licensing royalties, and the success of partnerships, with the metric standing at 2.50. The company's price chart on GURU.Markets visualizes the price action of the asset, whose XCART sales prospects depend on the completion of pre-commercial research stages.

Xenetic Biosciences (XBIO): Bagan rega target saka 04.07.2022 nganti 22.10.2026

Rincian analitis perusahaan Xenetic Biosciences (XBIO)

Indikator analitis utama xeneticbio.com (XBIO):

Kurs saham xeneticbio.com|XBIO - Prakiraan konsensus analis|Nilai pasar Xenetic Bio

Analisis fundamental perusahaan:Xenetic Biosciences Inc. (XBIO)

Produk asli Xenetic Biosciences

This indicator represents the arithmetic mean of target prices from leading financial institutions, which mitigates the impact of anomalous valuations from individual experts. The current consensus forecast for the security is 2.50, reflecting market expectations regarding the capitalization of Xenetic Biosciences (XBIO) given the potential of its innovative XCART platform in the personalized oncology therapy segment.

Perusahaan pesaing

beigene.com - Prakiraan gabungan firma investasi|Prakiraan konsensus analis HALO (Halozyme)|Revolution Medicines Inc - Bagan rega target|Ascentage - Prakiraan konsensus analis|Target median analis CG Oncology Therapeutics CGON|UroGen Pharma Ltd. (URGN) - Bagan rega target|Rata-rata rega prakiraan bicara.com (BCAX)|PSNL (Personalis) - Prakiraan konsensus analis|Target konsensus Erasca Inc (ERAS)|Prakiraan konsensus analis DCTH|Prakiraan konsensus analis Y-mAbs Corp (YMAB)|Bagan rega target Aura Biosciences, Inc. AURA|CADL: Prakiraan gabungan firma investasi|Accuray - Prakiraan konsensus analis|SELLAS Life Sciences (SLS) - Target konsensus|ACTU: Prakiraan konsensus analis|Rata-rata rega prakiraan Citius Oncology Inc (CTOR)|Bagan rega target TuHURA Biosciences Inc.|TARA: Konsensus nilai wajar|Target konsensus FATE (Fate Therapeutics)|WHWK (aadibio.com) - Konsensus nilai wajar|Prakiraan konsensus analis TCRX (TScan Therapeutics, Inc.)|CSBR - Target konsensus|XBIT: Target konsensus|CVM - Prakiraan konsensus analis|OS Therapies (OSTX) - Bagan rega target|Radiopharm Theranostics Ltd - Konsensus nilai wajar|ARTV (Artiva Biotherapeutics Inc.) - Prakiraan konsensus analis|Rata-rata rega prakiraan Adlai Nortye Limited ANL|Target konsensus VERU (Veru Inc.)|tempesttx.com - Prakiraan gabungan firma investasi|Prakiraan konsensus analis XLO (Xilio Therapeutics)|Renovaro Biosciences (RENB) - Rata-rata rega prakiraan|MURA - Bagan rega target|KAPA (Kairos Pharma Ltd) - Prakiraan gabungan firma investasi|OKUR: Prakiraan konsensus analis|Rata-rata rega prakiraan CytoMed Therapeutics Limited (GDTC)|Target konsensus CRIS|APLM (Apollomics Corp) - Rega prakiraan analis|Prakiraan konsensus analis THAR|Target median analis advanbiomed.com|Prakiraan konsensus analis GNPX (Genprex, Inc.)|CLDI - Target konsensus|SBFM: Target konsensus|Konsensus nilai wajar SLRX (Salarius Pharmaceuticals Inc)|PPBT: Prakiraan konsensus analis|AONC (American Oncology Network, Inc.) - Bagan rega target|BGNE (BeiGene, Ltd.) - Prakiraan konsensus analis|checkpointtx.com (CKPT) - Target median analis|Bagan rega target Elevation Oncology, Inc. (ELEV)|ICAD - Rata-rata rega prakiraan|Bagan rega target Ikena Oncology IKNA|Target median analis Notable Labs Corp (NTBL)|Viracta - Prakiraan konsensus analis|morphosys.com (MOR) - Target konsensus|NAYA: Prakiraan konsensus analis|AAPGV - Target median analis